CoronaVac
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | COVID-19 Vaccine (inactivated, adjuvanted) Valneva | — | 2023-10-12 | europa.eu ↗ |
| Approved | EU (EMA) | COVID-19 Vaccine (inactivated, adjuvanted) Valneva | — | 2022-06-24 | europa.eu ↗ |
Trials 47 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04551547 | Oct 2020 → Apr 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04383574 | May 2020 → Dec 2021 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04352608 | Apr → Jul 2020 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05150496 | Dec 2022 → Jan 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Suspended | No outcome recorded |
| Phase 2 | NCT07408297 | May 2022 → Jun 2024 | COVID-19 | Victoria Biomedical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT05254236 | Feb → Mar 2022 | COVID-19 | Sinovac Research and Development Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05087368 | Dec 2021 → Apr 2022 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 2 | NCT04992182 | Jul → Aug 2021 | COVID-19 | Universidad del Desarrollo | Unknown | No outcome recorded |
| Phase 2 | NCT04800133 | May 2021 → Mar 2025 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT04884685 | May → Aug 2021 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05156632 | Feb 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT05225285 | Jan → Jun 2022 | COVID-19 | Federal University of Espirito Santo | Unknown | No outcome recorded |
| Phase 3 | NCT05137418 | Nov 2021 → Jan 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05668065 | Nov 2021 → Jan 2022 | COVID-19 | Institut Pasteur de Tunis | Completed | No outcome recorded |
| Phase 3 | NCT04992260 | Sep 2021 → May 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04651790 | Nov 2020 → Aug 2022 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 3 | NCT04582344 | Sep 2020 → Jun 2022 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT04456595 | Jul → Dec 2020 | COVID-19 | Butantan Institute | Completed | No outcome recorded |
| Phase 427 trials | ||||||
| Phase 4 | NCT05165732 | Dec 2022 → Mar 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Suspended | No outcome recorded |
| Phase 4 | NCT05303584 | Apr → Jun 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05329038 | Apr → Jun 2022 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT05198336 | Jan 2022 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05148949 | Dec 2021 → Dec 2022 | COVID-19, pulmonary tuberculosis | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT05079217 | Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT05398926 | Dec 2021 → Jun 2022 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05105295 | Dec 2021 → Jun 2022 | COVID-19, HIV infectious disease | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05104216 | Dec 2021 → Jun 2022 | COVID-19, chronic bronchitis | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05057169 | Nov 2021 → Dec 2024 | — | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT05165966 | Oct 2021 → Apr 2022 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05499351 | Oct → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05075083 | Oct 2021 → Jun 2022 | COVID-19, chronic bronchitis | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05075057 | Oct 2021 → Jun 2022 | COVID-19, chronic bronchitis | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05075044 | Oct 2021 → Dec 2022 | COVID-19, HIV infectious disease | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05075070 | Oct 2021 → Jun 2022 | COVID-19, HIV infectious disease | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05298800 | Oct 2021 → Dec 2022 | — | Centers for Disease Control and Prevention, China | Unknown | No outcome recorded |
| Phase 4 | NCT04992208 | Jul 2021 → Mar 2023 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04953325 | Jul → Oct 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04962308 | Jun → Aug 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT04911790 | Jun 2021 → Jan 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04894227 | May 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04863638 | Apr → Dec 2021 | COVID-19 | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT04801667 | Mar → Oct 2021 | Orthocoronavirinae infectious disease, vaccinia | Hospital do Rim e Hipertensão | Unknown | No outcome recorded |
| Phase 4 | NCT04756830 | Feb → Sep 2021 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 4 | NCT04754698 | Feb 2021 → Nov 2023 | AIDS, COVID-19, rheumatic disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04747821 | Feb 2021 → Mar 2023 | COVID-19 | Butantan Institute | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04751721 | Feb → Mar 2021 | — | Izmir Bakircay University | Unknown | No outcome recorded |
| — | NCT04751695 | Feb → Mar 2021 | — | Izmir Bakircay University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 32 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05918939 Comparator | Sep 2022 → Aug 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05583357 Comparator | Aug → Sep 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT05928455 Comparator | May → Oct 2022 | COVID-19, vaccinia | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06113744 Comparator | Mar → Jun 2023 | COVID-19 | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05897190 Comparator | May → Jun 2022 | Orthocoronavirinae infectious disease | Argorna Pharmaceuticals Co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT05228613 Comparator | Feb → Aug 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Phase 1 | NCT05067894 Comparator | Dec 2021 → Apr 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05043259 Comparator | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06113731 Comparator | Jul → Oct 2023 | COVID-19 | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05465902 Comparator | Jul 2023 → Nov 2024 | COVID-19 | WestVac Biopharma Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05593042 Comparator | Nov 2022 → Oct 2023 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 2 | NCT05463354 Comparator | Jul → Aug 2022 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05323435 Comparator | May → Jul 2022 | COVID-19 | Jiangsu Rec-Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05230940 Comparator | Feb 2022 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 2 | NCT04979949 Comparator | Jul 2021 → Mar 2022 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05463419 Comparator | Oct 2022 → Dec 2023 | — | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT05433272 Comparator | Aug → Sep 2023 | COVID-19 | Sinovac Biotech (Colombia) S.A.S. | Unknown | No outcome recorded |
| Phase 3 | NCT05428592 Comparator | Apr → Oct 2023 | Orthocoronavirinae infectious disease | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05683561 Comparator | Jan → Aug 2023 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05508477 Comparator | Jun 2022 → Mar 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05188677 Comparator | Jun 2022 → Jun 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 3 | NCT05381350 Comparator | Jun → Sep 2022 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05382871 Comparator | May 2022 → Jul 2023 | COVID-19 | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05374954 Comparator | May → Sep 2022 | COVID-19 | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05077176 Comparator | Oct 2021 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT04942405 Comparator | Jun 2021 → Mar 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT04993365 Comparator | Nov 2021 → Jul 2022 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04952727 Comparator | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04892459 Comparator | May → Jul 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04775069 Comparator | May 2021 → Sep 2023 | liver disorder | Humanity & Health Medical Group Limited | Completed | No outcome recorded |
| Phase 4 | NCT04789356 Comparator | Mar → Jul 2021 | COVID-19 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06381843 Comparator | Aug 2022 → Mar 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 82 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoronaVac | “A Randomized, Open, Control Phase ⅠV Clinical Trial, to Evaluate One Booster Immunization of Inactivated COVID-19 Vaccine (CoronaVac) or Original Vaccine in Adults Aged 18-45...” NCT05165732 ↗44“One of the vaccines developed, the China-based CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the...” NCT04751721 ↗ “Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents...” PMID 34197764 ↗ Jun 2021 “This study will assess safety and immunogenicity of the inactivated vaccine adsorbed against COVID-19 (CoronaVac) in a population of healthy individuals older than 18 years of age.” NCT04756830 ↗ “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 2024 “We did a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial of CoronaVac in healthy adults aged 60 years and older in Renqiu (Hebei, China).” PMID 33548194 ↗ Feb 2021 “CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the classic vaccine production method.” NCT04751695 ↗ “Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity.” PMID 36441137 ↗ Nov 2022 “This study is an open phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.” NCT05198336 ↗ “The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China.” PMID 36383021 ↗ Nov 2022 “Kidney transplant recipients aged 30-69 y with >30 d of transplantation received two 3 µg intramuscular doses of CoronaVac 28 d apart” PMID 34882589 ↗ Apr 2022 “First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.” NCT05668065 ↗ “CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use” PMID 36226829 ↗ Oct 2022 “investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19” PMID 33217362 ↗ Nov 2020 “CoronaVac, an inactivated SARS-CoV-2 vaccine, was one of the first deployed during the COVID-19 pandemic.” PMID 42329996 ↗ Jun 2026 “Sinopharm's BBIBP-CorV and Sinovac's CoronaVac are inactivated whole-virus COVID-19 vaccines.” NCT07408297 ↗ “or a homologous intramuscular vaccination with CoronaVac (0·5 mL).” PMID 35605625 ↗ May 2022 “third dose of inactivated COVID-19 vaccine(CoronaVac)” NCT05499351 ↗ “an inactivated vaccine (CoronaVac) previously” PMID 37360864 ↗ Jun 2023 “inactivated COVID-19 vaccine (CoronaVac®)” PMID 39313857 ↗ Sep 2024 “inactivated COVID-19 vaccine (CoronaVac)” NCT05148949 ↗ “One standard IM CoronaVac dose (0.5 mL)” NCT04992182 ↗ |
| Known as | Adsorbed COVID-19 (Inactivated) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04747821 ↗ |
| Known as | CoronaVac vaccine | “One of the vaccines developed, the China-based CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the...” NCT04751721 ↗ |
| Known as | COVID-19 Vaccine (Vero Cell), Inactivated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05374954 ↗ |
| Known as | COVID-19 Vaccine (Vero cell), Inactivated (CZ strain) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05381350 ↗ |
| Known as | COVID-19 Vaccine,Inactivated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156632 ↗ |
| Known as | Covilo | “In this prospective cohort study, we analyzed the safety and immunogenicity of a two-dose schedule of the inactivated COVID-19 vaccine (Covilo) in people living with HIV (PLWH).” PMID 40838719 ↗ Aug 20251“Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirates.” PMID 38529685 ↗ Apr 2024 |
| Known as | Inactivated Covid-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463419 ↗ |
| Known as | Inactive SARS-CoV-2 vaccine (Vero cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04892459 ↗ |
| Known as | SARS-CoV-2 Inactivated Vaccine | “SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection” NCT05079217 ↗6“SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection” NCT04992208 ↗ “SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection” NCT04911790 ↗ |
| Known as | Sinovac | “The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).” NCT04775069 ↗1“two-doses CoronaVac (Sinovac) vaccine” NCT05230940 ↗ |
| Known as | Sinovac CoronaVac | “two doses of an inactivated SARS-CoV-2 vaccine-Sinovac CoronaVac.” PMID 35605625 ↗ May 2022 |
| Modality | Vaccine | “candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2” PMID 33548194 ↗ Feb 2021 |
| Route | Intramuscular | “Vaccine or placebo was given by intramuscular injection in two doses (days 0 and 28).” PMID 33548194 ↗ Feb 2021 |